GlassScriptPhysician profile
Mateusz Zagata
NPI 1205070711
$3,612.47
in general payments reported to CMS, 2019-2025
27 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $284 · 2021: $733 · 2022: $516 · 2023: $703 · 2024: $623 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.00 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $463.49 | 2019-2024 | |
| Amgen INC. | $458.41 | 2020-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $364.68 | 2020-2024 | Jardiance, Mounjaro, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.20 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $317.00 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $300.90 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $187.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $141.46 | 2021-2024 | |
| Astellas Pharma US INC | $119.36 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.40 | 2019-2023 | Jardiance, Synjardy |
| Novo Nordisk INC | $116.23 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $105.71 | 2019-2025 | Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $88.54 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $64.04 | 2020-2022 | |
| Philips North America LLC | $60.33 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $55.20 | 2019-2021 | |
| Abbott Laboratories | $44.55 | 2024-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $39.50 | 2019 | |
| Boston Scientific Corporation | $36.86 | 2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $36.15 | 2025 | |
| Nestle Healthcare Nutrition INC. | $25.45 | 2021 | |
| Corcept Therapeutics | $21.26 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $20.66 | 2021 | |
| Shire North American Group INC | $20.64 | 2019 | |
| Medtronic Vascular, INC. | $20.16 | 2020 | |
| Sanofi Pasteur INC. | $18.20 | 2023 | |
| Shionogi INC | $17.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mateusz Zagata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.